Xenometrix, Inc.

Xenometrix, Inc. developed proprietary gene response profiling and genotoxicity technologies to enable high throughput screening for genotoxicity, helping the pharmaceutical industry improve the effectiveness of drug discovery and development through lead compound optimization. The company's goal was to accelerate the selection of promising drug and chemical leads for pharmaceutical, chemical, and biotechnology industries. The company's bioinformatics team assembled a database of gene profiles for public domain pharmaceuticals.

Xenometrix, Inc., based in Denver, Colorado, was founded in 1991, and acquired by Discovery Partners International in 2001.